Precision Cardiology Market Size, Share & Trends Analysis Report By Offering (Service, Product), By Sample (Blood, Non-Blood, Saliva, Buccal swabs), By Technology (Sequencing, Polymerase Chain Reaction (PCR), Microarray), By Application (Cardiomyopathy, Arrhythmia, Aortopathy and Vascular Diseases, Familial Hypercholesterolemia (FH), Congenital Heart Defects and Syndromes), By End-User (Hospitals and Clinics, Diagnostic Laboratories, Academic and Research Institute) and By Region (North America, Europe, APAC, Middle East and Africa, LATAM) Forecasts, 2026-2034

Precision Cardiology Market Size

The global precision cardiology market size was valued at USD 3.10 billion in 2025 and is projected to grow from USD 3.48 billion in 2026 to USD 8.95 billion by 2034, registering a CAGR of 12.5% during the forecast period from 2026 to 2034. North America dominated the precision cardiology market with a market share of 42.6% in 2025.

The precision cardiology sector is one of the most constantly growing and dynamic markets, according to healthcare specialists. As the prevalence of cardiovascular disease rises, so does the demand for early screening and sequencing.

Medical practitioners that practice precision cardiology take a multidisciplinary approach to treating and preventing cardiovascular disease by taking into account the unique interactions between an individual's genetics, lifestyle, and environmental exposures. Rather than relying on a single path phenotype for all individuals with the same symptoms, this approach takes into account the unique characteristics of each individual patient and treats them as such. Because of the growing burden of cardiovascular illness, the increased emphasis on early disease screening, and the reducing cost of sequencing technology, the precision cardiology business is currently experiencing a growth spurt.

The advancement of precision cardiology tests based on cutting-edge sequencing technology is expected to help doctors make more informed clinical judgments in the field of cardiovascular care. To find new genetic biomarkers related to cardiovascular illness and use them in the creation of new medicines, researchers can use enhanced precision cardiology tests developed by the scientific community. Precision cardiology market growth is being fuelled by a number of causes, including the increasing use of research-based product offerings by academic and research institutions, as well as considerable investments by rising and legacy companies.

Offering Analysis

The market is segmented into two categories, Service and Product. The market was dominated by the service category. Precision cardiology services will control 80% of the market by 2021. Precision medicine in clinical settings is to blame for this. Because of the rising numbers of people with diabetes and pre-diabetes, as well as the expanding number of sedentary people, there is a compounding effect on the global burden of cardiovascular disease (CVD).

Request Customizationto receive a tailored report.

Sample Analysis

The market is segmented into two segments, Blood and Non-Blood. Non-blood samples have the highest growth rates. It is expected that the use of non-blood samples would grow rapidly between 2021 and 2030. Non-blood samples have been used for precision assays in the medical field for years. There is also an increase in the sales of non-blood samples such as saliva and buccal swabs due to the development of novel tests by market players.

Technology Analysis

The market is segmented into Sequencing, Polymerase Chain Reaction (PCR) and Microarray. Diagnostic sequencing that is based on precision maximizes income. More than $600 million was earned in sequencing revenue in 2021. There is a good chance that this category will follow suit in the years ahead. In light of its high precision, low sequencing cost, wide coverage, and scalability, the technology is widely used.

Application Analysis

The market is segmented into Cardiomyopathy, Arrhythmia, Aortopathy and Vascular Diseases, Familial Hypercholesterolemia (FH) and Congenital Heart Defects and Syndromes. Application of cardiomyopathy treatment proved to be crucial. More than $800 million will be generated by the cardiomyopathy application by 2030. There has been an increase in the prevalence of cardiomyopathies worldwide, as well as a rise in the use of precision medicine. Alcoholic cardiomyopathy affected 708,000 people in 2019, according to the American College of Cardiology.

End-User Analysis

The market is segmented into Hospitals & Diagnostic Laboratories and Academic & Research Institutes. There is a lot of cardiovascular testing at hospitals and diagnostic labs. Precision cardiology testing is used in hospitals and diagnostic laboratories to identify cardiovascular disease (CVDs). A wide range of pathology and advanced diagnostics are available in medical facilities and labs. They offer cutting-edge testing for biomarker analysis and CVD consulting at these facilities, as well.

Speak to an Analystto discuss market opportunities.

Regional Insights

The global precision cardiology market share is segmented by geography into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa.

North America Dominates the Global Market

North America is leading the global market by having the biggest revenue percentage in the market for precision cardiology. This can be attributed to the presence of important market players in the United States as well as the growing acceptance of technologically enhanced products and services in clinical and research environments.

Precision cardiology has the largest share in North America due to the presence of market leaders like Laboratory Corporation of America Holdings, Illumina, Inc., PerkinElmer Inc., Thermo Fisher Scientific Inc. and Quest Diagnostics Incorporated, as well as the significant adoption of high-fidelity precision cardiology tests to diagnose cardiovascular diseases. As a result of these reasons, the North American market for precision cardiology is expected to grow in the near future. Furthermore, government activities aimed at establishing a link between genetic biomarkers and cardiovascular care have had a substantial impact on the regional industry.

A major contribution to the creation of effective and acceptable guidelines and policies for the regional adoption of precision medical products and services has been made by FDA and the Clinical Laboratory Improvement Amendments (CLIA) in the United States. Due to a dynamic marketplace and an increasing number of new organizations making end-to-end offerings, the North American market is expected to maintain its leadership position over the forecast period.

Unlock Regional Insightsto access country-level data, & regional trends.

Asia-Pacific: Rapidly Growing Region

The Asia-Pacific area is also expected to develop at the highest CAGR throughout the forecast period, which runs from 2022 to 2030. To put it simply, the underlying causes include an increase in cardiovascular disease incidence, a rise in healthcare knowledge, and a stable economy that has led to a stronger concentration on research and the use of precision cardiology testing.

List of Key and Emerging Players in Precision Cardiology Market